Aurobindo Pharma's Generic Approval and Market Entry

The U.S. Food and Drug Administration (FDA) has granted final approval for Aurobindo Pharma's generic version of adapalene and benzoyl peroxide 0.3%/2.5% gel (ANDA 217384) on July 22, 2026. This approval marks the official launch of a generic alternative to Galderma's Epiduo Forte. Epiduo Forte is a high-concentration combination of adapalene, a retinoid, and benzoyl peroxide, an antibacterial agent, and has been widely used to treat acne. With this approval, Aurobindo Pharma is poised to significantly strengthen its portfolio in the competitive U.S. dermatology generics market.

Synergistic Acne Treatment Through Combined Action

This product exhibits excellent efficacy in treating moderate to severe acne through the combined action of its two active ingredients. Adapalene works by acting on retinoic acid receptors, preventing the accumulation of keratin in pores and inhibiting inflammatory lesions. Meanwhile, benzoyl peroxide kills acne-causing bacteria (Cutibacterium acnes) and dissolves keratin, complementing the action of adapalene. By providing the benefits of combination therapy in a single formulation, this product enhances patient compliance and reduces treatment duration, offering significant clinical value.

Changing Competitive Landscape in the U.S. Acne Treatment Market

The U.S. market for the original drug, Epiduo Forte, is estimated at approximately $200 million annually. With the entry of Aurobindo Pharma's generic, price competition is inevitable not only with the original developer, Galderma, but also with existing generic competitors such as Zydus and Alembic. In particular, the recent trend in the U.S. towards cost reduction in healthcare and a preference for affordable generics is likely to benefit Aurobindo Pharma in securing an early share of the prescription market. As a result, original pharmaceutical companies are expected to actively seek defensive strategies such as patent protection, price reductions, or over-the-counter (OTC) conversion.

Accelerated Generic Competition and Price Reduction

This FDA approval is significant in that it provides U.S. dermatologists and acne patients with an affordable treatment alternative. The supply of AB-rated generics, which are eligible for insurance coverage, will significantly reduce patients' out-of-pocket costs compared to expensive brand-name drugs. Furthermore, a competitive environment with multiple generic manufacturers will drive down overall drug prices, reducing the financial burden on public and private insurers. As a result, access to expensive dermatology treatments will be greatly improved, and the widespread adoption of standard acne treatments is expected to accelerate.